Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions-Reference-Cited by-同舟云学术

Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions

Published:2010-12-14 Issue:1 Volume:6 Page:5-12
ISSN:1558-8211
Container-title:Current Hematologic Malignancy Reports
language:en
Short-container-title:Curr Hematol Malig Rep

Author:

Navada Shyamala C.,Silverman Lewis R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11899-010-0071-9.pdf

Reference49 articles.

1. Silverman LR: The myelodysplastic syndrome. In Cancer Medicine, edn 8. Edited by Hong WK, Bast RC Jr, Hait WN, et al. Shelton, CT: PMPH-USA; 2010:1544–1558.

2. Goldberg SL, Chen E, Corral M, et al: Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries. J Clin Oncol 2010, 28: 2847–2852.

3. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189–199.

4. Greenberg P, Cox C, Lebeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89: 2079–2088.

5. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100: 2292–2302.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Azacytidine for the treatment of myelodysplastic syndromes;Expert Opinion on Pharmacotherapy;2013-04-27

2. Update on the Science of Myelodysplastic Syndromes;Clinical Journal of Oncology Nursing;2012-05-28